New Data Showing that Transgene and NEC’s TG4050 induces strong and specific immune responses against tumors presented at AACR 15
Category: dates
Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer
A. Lalane et al.AACR 2023Download the poster herePoster Presentation
A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) human papilloma virus (HPV)-16 positive anogenital cancers
C. Le Tourneau et al.AACR 2023Download the poster herePoster Presentation
Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators
JB. Marchand et al.AACR 2023Download the poster herePoster Presentation
Transgene – Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR
Preclinical results showing TG6050 induces tumor regression by activating innate and adaptive immune responses 15
TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses
JB. Marchand et al.AACR 2023Download the poster herePoster Presentation
Extracellular vesicles (EV): mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses
L. Walther et al.AACR 2023Download the poster herePoster Presentation
Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director
Appointment of Carol Stuckley as New Independent Director 15
Availability of Preparatory Documents for the Combined General Meeting of May 5, 2023
Availability of Preparatory documents for the combined general meeting of May 5, 2023 15
Availability of Transgene’s 2022 Universal Registration Document
Availability of Transgene’s 2022 Universal Registration Document 15